SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Belcaro, G.
Right arrow Articles by De Simone, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belcaro, G.
Right arrow Articles by De Simone, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Long-Term Evaluation of Indobufen in Peripheral Vascular Disease

G. Belcaro

Laboratorio di Microcircolazione Cardiovascular Institute Universita' Abruzzese G.D' Annunzio, Chieti

P. De Simone

Farmitalia-C. Erba, Milan, Italy

Indobufen—an inhibitor of platelets aggregation—has been used in 306 pa tients with intermittent claudication due to peripheral vascular disease. Patients were treated and followed up for one year. One patient of every 3 treated with indobufen was treated with ASA, and a control group of patients receiving no treatment was also followed up. The authors studied by means of a treadmill exercise test the pain-free walking distance (PFWD), the global walking distance (GWD), and the recovery time after exercise. The treatment period was com pleted by 290 patients: 204 claudicants, 51 claudicants with diabetes, and 35 with a short PFWD and GWD (>150 m). Indobufen was more effective than ASA in improving the PFWD and GWD in all groups. There were also fewer side effects with indobufen, and cardiac morbidity and mortality was also reduced.

In conclusion indobufen showed its activity and safety in chronic treatment of patients with peripheral disease, and we suggest that it may be used for long periods without side effects.

Angiology, Vol. 42, No. 1, 8-14 (1991)
DOI: 10.1177/000331979104200102
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
E. Panchenko, A. Eshkeeva, A. Dobrovolsky, E. Titaeva, Ya. Podinovskaya, K.M.A. Hussain, Yu. Karpov, and E. Panchenko
Effects of Indobufen and Pentoxifylline on Walking Capacity and Hemostasis in Patients with Intermittent Claudication: Results of Six Months of Treatment
Angiology, March 1, 1997; 48(3): 247 - 254.
[Abstract] [PDF]


Advertisement